The Conversation (0)
Matinas BioPharma (NYSE:MTNB), a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications, today formally announced its financial results for the year ended December 31, 2017. As quoted in the press release: “During 2017, we made solid progress in our clinical development and the understanding of our proprietary cochleate platform delivery technology. We firmly …
Matinas BioPharma (NYSE:MTNB), a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications, today formally announced its financial results for the year ended December 31, 2017.
As quoted in the press release:
“During 2017, we made solid progress in our clinical development and the understanding of our proprietary cochleate platform delivery technology. We firmly believe in the potential of our lead product, MAT2203, and our streamlined development path moving forward towards addressing a significant unmet medical need in the prevention of invasive fungal infections (“IFIs”). In parallel, we continue to be aggressive in advancing our strategy to collaborate with established pharmaceutical companies to expand the utilization of our delivery technology,” commented Jerome D. Jabbour, Chief Executive Officer of Matinas.
Click here to read the full press release.
